ArticleFrontiers in public health2022
Long-term trends in the burden of inflammatory bowel disease in China over three decades: A joinpoint regression and age-period-cohort analysis based on GBD 2019.
Article in Frontiers in public health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 108 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
108 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Effectiveness and safety of vedolizumab in real-world studies in Asian patients with inflammatory bowel disease: a systematic review and meta-analysis.BMC gastroenterology · 2026Pooled it
- The disease burden of ILD at the global, regional, and national levels from 1990 to 2021, and projections until 2035: the 2021 Global Burden of Disease study.Frontiers in medicine · 2025Pooled it
- Impact of Climate Warming on All-Causes Mortality in China: The Role of Non-Optimal Temperature Exposure and Multi-Scenario Projections to 2050.GeoHealth · 2026Article
- Inflammatory bowel disease burden in China and the United States from 1990-2023 and prediction to 2050.Internal and emergency medicine · 2026Article
- Trends and health inequalities in the global burden of kidney cancer from 1990 to 2021, with projections to 2040.Medicine · 2026Article
- Disability among Palestinian patients with inflammatory bowel disease: evaluation using the IBD Disk and identification of associated factors.Crohn's & colitis 360 · 2026Article
- Gut Microbiota in Irritable Bowel Syndrome and Inflammatory Bowel Disease: Differences in Pathophysiology, Biomarkers, and Treatment Implications.Pharmaceuticals (Basel, Switzerland) · 2026Review
- From past patterns to future preparedness: a secondary analysis of the Global Burden of Disease Study 2021 on neonatal communicable disease burden in China and the Asia-Pacific region, 1990-2035.Translational pediatrics · 2026Article
- NCOA4-mediated ferritinophagy modulates colitis-associated ferroptosis in intestinal epithelial cells and mucosal repair.Biology direct · 2026Article
- Rising burden of fall-induced hip fractures in China: accelerating male-specific trends and persistent gender disparities from Global Burden of Disease 2021.Acta orthopaedica et traumatologica turcica · 2026Article
- The rising tide of opioid use disorder: analyzing 30 years of epidemiological trends and socioeconomic factors in the U.S.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Distribution and trends of the global burden of female infertility attributable to sexually transmitted infections from 1990 to 2021.BMC infectious diseases · 2026Article
- Burden and trends of decubitus ulcers in East Asia, 1990-2021, with projections to 2031: a comprehensive analysis of the global burden of disease study.Journal of health, population, and nutrition · 2026Article
- Global burden of inflammatory bowel disease in Group 20 countries, 1990 to 2021: A systematic analysis with projections to 2050.Medicine · 2026Article
- C-Type lectin receptors as key modulators of intestinal inflammation: insights into IBD pathogenesis and therapy.FEMS microbiology letters · 2026Review
- Factors associated with kinesiophobia in patients with inflammatory bowel disease: associations with functional independence and fatigue.Frontiers in medicine · 2026Article
- Trends in PCOS Incidence, Prevalence, and DALYs Across Five BRICS Nations, 1990-2050: A Decomposition, Age-Period-Cohort, and Bayesian Forecasting Analysis Based on GBD 2021.International journal of women's health · 2026Article
- Evaluation of Needs for Chronic Disease Management Services in Patients with Inflammatory Bowel Disease Based on the Kano Model: A Cross‑Sectional Study.Patient preference and adherence · 2026Article
- Disease burden of asbestos-related diseases in China (1990-2023) based on GBD estimates: A call for stronger labor protection laws.PloS one · 2026Article
- Spatiotemporal patterns and incidence trends of other infectious diarrhea in Qinghai Province, 2009-2023: a surveillance-based analysis.Frontiers in public health · 2026Article
48 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: To study the corresponding strategies to control inflammatory bowel disease (IBD), a comprehensive assessment of the disease burden is required. Herein, we present long-term trends in the burden of IBD in China over the last three decades, as well as its epidemiological features. Methods: We characterized the burden of IBD in China using the GBD 2019 methods and results, based on prevalence, incidence, mortality, years lost (YLLs), years lived with disability (YLDs), and disability-adjusted life years (DALYs) estimated using the DisMod-MR 2-1. We also used joinpoint and age-period-cohort (apc) analysis methods to interpret IBD epidemiological characteristics and compare them to global prevalence trends. Results: The age-standardized incidence and mortality rates in both sexes changed from 1.47 (95% CI: 1.24, 1.74) to 3.01 (95% CI: 2.59, 3.50) and from 0.86 (95% CI: 0.59, 1.16) to 0.30 (95% CI: 0.24, 0.35) per 100,000 people in China from 1990 to 2019. The age-standardized DALY rate in China decreased from 24.47 (95% CI: 17.88, 30.19) per 100,000 people in 1990 to 13.10 (95% CI: 10.29, 16.31) per 100,000 people in 2019. The average annual percentage change (AAPC) in age-standardized incidence, prevalence, and mortality rates for IBD in China were 2.51 (95% CI: 2.44, 2.57), 2.53 (95% CI: 2.41, 2.66), and -3.62 (95% CI: -3.85, -3.39). The effects of age, period, and cohort on incidence and mortality rates differed. Conclusions: The increasing age-standardized prevalence rates are contributed to by the reduction in age-standardized mortality rates and DALYs, compounded by the rise in the age-standardized incidence rates between 1990 and 2019 in China. The burden of IBD in China will be a major public health challenge, given the country's large population base and aging population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.